7-nitroindazole has been researched along with Parkinson Disease, Secondary in 4 studies
7-nitroindazole: an inhibitor of nitric oxide synthase; exhibits anti-nociceptive activity without increasing blood pressure
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole, has previously been shown to be protective in animal models of Parkinson's disease in vivo." | 1.31 | The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. ( Boireau, A; Bordier, F; Dubedat, P; Imperato, A; Moussaoui, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yuste, JE | 1 |
| Echeverry, MB | 1 |
| Ros-Bernal, F | 1 |
| Gomez, A | 1 |
| Ros, CM | 1 |
| Campuzano, CM | 1 |
| Fernandez-Villalba, E | 1 |
| Herrero, MT | 1 |
| Hantraye, P | 1 |
| Brouillet, E | 1 |
| Ferrante, R | 1 |
| Palfi, S | 1 |
| Dolan, R | 1 |
| Matthews, RT | 1 |
| Beal, MF | 1 |
| Di Monte, DA | 1 |
| Royland, JE | 1 |
| Jakowec, MW | 1 |
| Langston, JW | 1 |
| Boireau, A | 1 |
| Dubedat, P | 1 |
| Bordier, F | 1 |
| Imperato, A | 1 |
| Moussaoui, S | 1 |
4 other studies available for 7-nitroindazole and Parkinson Disease, Secondary
| Article | Year |
|---|---|
7-Nitroindazole down-regulates dopamine/DARPP-32 signaling in neostriatal neurons in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Enzyme Inh | 2012 |
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 1996 |
Role of nitric oxide in methamphetamine neurotoxicity: protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Temperature; Dopamine Agents; Enzyme Inhibitors; Homov | 1996 |
The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2000 |